Published in Plast Reconstr Surg on August 01, 1992
Does cosmetic surgery improve psychosocial wellbeing? Med J Aust (2002) 1.81
Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q (2004) 1.00
The Presentation of Body Dysmorphic Disorder in Medical Settings. Prim psychiatry (2006) 0.91
Body dysmorphic disorder and cosmetic dermatology: more than skin deep. J Cosmet Dermatol (2004) 0.81
Plastic surgery and psychotherapy in the treatment of 100 psychologically disturbed patients. Plast Reconstr Surg (1991) 2.19
Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry (2000) 5.21
Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry (1993) 4.57
Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med (1999) 4.54
What is a mental/psychiatric disorder? From DSM-IV to DSM-V. Psychol Med (2010) 4.33
Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA (1999) 3.82
A current view of the interface between borderline personality disorder and depression. Am J Psychiatry (1991) 3.69
The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry (1998) 3.26
Psychiatric features of individuals with problematic internet use. J Affect Disord (2000) 3.19
Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 3.17
A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry (2000) 2.88
The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord (2001) 2.43
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2000) 2.34
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry (2000) 2.34
Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation (2000) 2.09
The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA (1994) 2.08
Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry (1989) 2.07
Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther (2009) 1.99
Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry (1989) 1.94
12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry (1998) 1.91
Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry (1998) 1.86
Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs (2001) 1.74
The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol (2001) 1.72
Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics (1998) 1.59
The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry (1999) 1.58
Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol (2005) 1.58
A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull (1994) 1.58
Deciding where and how to be tested for HIV: what matters most? J Acquir Immune Defic Syndr (2001) 1.54
Obsessive compulsive spectrum disorder. J Clin Psychiatry (1994) 1.54
Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet (1994) 1.52
Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry (1986) 1.47
Personality disorders, history of trauma, and posttraumatic stress disorder in subjects with anxiety disorders. Compr Psychiatry (2001) 1.45
Are impulse-control disorders related to bipolar disorder? Compr Psychiatry (1996) 1.42
Rash complicating carbamazepine treatment. J Clin Psychopharmacol (1994) 1.42
Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry (1998) 1.40
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry (1999) 1.40
Thirty-three cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry (1999) 1.40
A pilot study of rapid lithium administration in the treatment of acute mania. Bipolar Disord (2001) 1.39
A screening questionnaire for body dysmorphic disorder in a cosmetic dermatologic surgery practice. Dermatol Surg (2001) 1.37
Underreporting of assaults on staff in a state hospital. Hosp Community Psychiatry (1981) 1.33
A comparison study of body dysmorphic disorder and obsessive-compulsive disorder. J Clin Psychiatry (1998) 1.31
Characteristics of memory dysfunction in body dysmorphic disorder. J Int Neuropsychol Soc (2000) 1.30
Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci (2000) 1.30
A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry (2000) 1.28
Evolution of the cerebellar cortex: the selective expansion of prefrontal-projecting cerebellar lobules. Neuroimage (2009) 1.28
Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med (2000) 1.24
Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry (1998) 1.20
Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry (1991) 1.18
Personality disorders and traits in patients with body dysmorphic disorder. Compr Psychiatry (2000) 1.18
Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry (2000) 1.18
Role of HIV counseling and testing in changing risk behavior in developing countries. AIDS (1995) 1.17
Twelve-month outcome in bipolar patients with and without personality disorders. J Clin Psychiatry (2000) 1.17
An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol (1999) 1.15
Who seeks HIV testing? The impact of risk, knowledge, and state regulatory policy on the testing decision. Inquiry (1991) 1.15
Coronary angioplasty. Statewide experience in California. Circulation (1993) 1.15
Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord (2001) 1.14
Treatment of habit-tic deformity with fluoxetine. Arch Dermatol (1997) 1.13
Assaults on psychiatrists by patients. Am J Psychiatry (1976) 1.12
The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord (2001) 1.11
Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull (1997) 1.11
Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J Clin Psychiatry (1998) 1.11
Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry (2001) 1.10
Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? J Clin Psychiatry (1995) 1.09
Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry (1991) 1.09
Undiagnosed HIV infection in acute care hospitals. N Engl J Med (1992) 1.07
Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry (1996) 1.07
Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population. J Affect Disord (2000) 1.06
Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics (1999) 1.06
Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry (1998) 1.06
Lycanthropy: alive and well in the twentieth century. Psychol Med (1988) 1.05
Body dysmorphic disorder in men. BMJ (2001) 1.05
Comparison of obese men and women with binge eating disorder seeking weight management. Eat Weight Disord (2007) 1.03
Attention deficit hyperactivity disorder in adolescent mania. Am J Psychiatry (1995) 1.03
Racial influence on diagnosis in psychotic mania. J Affect Disord (1996) 1.01
Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry (1996) 1.01
Chronology of comorbid and principal syndromes in first-episode psychosis. Compr Psychiatry (1995) 1.00
Perceived stress in body dysmorphic disorder. J Nerv Ment Dis (1998) 0.99
Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry (2000) 0.99
The psychiatric diagnoses of twenty-two adolescents who have sexually molested other children. Compr Psychiatry (1999) 0.99
Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry (1995) 0.98
Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry (2001) 0.98
Muscle dysmorphia. J Clin Psychiatry (1997) 0.98
Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry (2000) 0.97
Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry (1987) 0.97
Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord (2001) 0.96
Lithium in the treatment of a manic patient with multiple sclerosis: a case report. Dis Nerv Syst (1977) 0.96
Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol Psychiatry (2003) 0.96
Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety (1997) 0.95
Linkage of a bipolar disorder susceptibility locus to human chromosome 13q32 in a new pedigree series. Mol Psychiatry (2003) 0.94
Fatal body dysmorphic disorder by proxy. J Clin Psychiatry (2001) 0.93
Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet (2003) 0.92
Suicidality among patients with mixed and manic bipolar disorder. Am J Psychiatry (1996) 0.92
Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci (1995) 0.91
The effects of race and information variance on disagreement between psychiatric emergency service and research diagnoses in first-episode psychosis. J Clin Psychiatry (1997) 0.91
Prevalence of self-reported arm morbidity following treatment for breast cancer in the Australian Breast Cancer Family Study. Breast (2001) 0.91
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry (2000) 0.90
Evaluating the parent-of-origin effect in bipolar affective disorder. Is a more penetrant subtype transmitted paternally? J Affect Disord (2000) 0.90
Avascular necrosis of bone: a manifestation of Cushing's disease. South Med J (1986) 0.90
Body dysmorphic disorder: does it have a psychotic subtype? J Clin Psychiatry (1993) 0.90